PRESENTATION

Q4 2020 — Presentation

Q4 2020PDF · 16 pages776 KB
DANAHER CORPORATION
Fourth Quarter 2020 Earnings Release
January 28, 2021

-- 1 of 16 --

2
Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated future financial performance and any other statements regarding events or developments
that we anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results,
developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking
statements. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business and
community responses thereto) on our business, results of operations and financial condition, Danaher's ability to successfully integrate the operations and employees of the Biopharma business Danaher
acquired from General Electric Company (now known as Cytiva) with Danaher's existing business, the ability to realize anticipated financial, tax and operational synergies and benefits from such acquisition,
Cytiva's performance and maintenance of important business relationships, the impact of our debt obligations (including the debt incurred to finance the acquisition of Cytiva) on our operations and liquidity,
deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), developments and uncertainties in U.S. policy stemming from the
U.S. administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to
develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with
applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost
reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and
other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures
(including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data
privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in
our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety
matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product
liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties,
commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our
products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's separation from the EU and uncertainty relating to
the terms of such separation), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional information regarding the factors that may
cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2019 Annual Report on Form 10-K and our first, second and third quarter 2020
Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentation and except to the extent required by applicable law, the Company does not assume any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in
the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various financial metrics the
presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please refer to our earnings release and
the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the heading “Financial Reports” and subheading “Quarterly
Earnings,” as well as our Annual Report on Form 10-K for the year ended December 31, 2020 when it is filed. All references in this presentation (1) to financial metrics relate only to the continuing operations of
Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may also describe certain products and
devices which have applications submitted and pending for certain regulatory approvals.

-- 2 of 16 --

2020 Performance Summary: Revenue
Amounts shown are in $ millions.
Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” “Core,” "Core including Cytiva," and “FX,” please refer to the
accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
Q4 REVENUE
+39.0%
Core including Cytiva +15.5%
FY REVENUE
+24.5%
Core including Cytiva +9.5%

-- 3 of 16 --

2020 Performance Summary: Operating Profit Margin
Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as discontinued operations, "Other" refers to certain
acquisition-related fair value adjustments and incremental transaction costs deemed significant and integration preparation costs associated with the acquisition of Cytiva and impairment charges related to a facility in the Diagnostics segment and trade names and other
intangible assets in the Environmental & Applied Solutions segment, and “Core” refers to all other year-over-year operating profit margin changes; for further description of these items, please refer to the accompanying information required by Regulation G, located at the end
of this presentation and on the "Investors" section of Danaher's website.
Q4 OPERATING PROFIT MARGIN 	FY OPERATING PROFIT MARGIN
+390 bps
Core +360 bps
Acquisitions +60 bps
Other -30 bps
Core +170 bps
Acquisitions +125 bps
Other -225 bps
+70 bps

-- 4 of 16 --

2020 Performance Summary: Adjusted Diluted Net EPS
Q4 ADJ. DILUTED NET EPS 	FY ADJ. DILUTED NET EPS
+62.5% 	+43.0%
For the definition of Adjusted Diluted Net EPS, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.

-- 5 of 16 --

2020 Performance Summary: Free Cash Flow Performance
Q4 FREE CASH FLOW 	FY FREE CASH FLOW
+133.5% 	+79.0%
Amounts shown are in $ millions.
For the definition of Free Cash Flow, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.

-- 6 of 16 --

Fourth Quarter 2020: Life Sciences
7
OPERATING PROFIT MARGIN
+75.5%
Core including Cytiva +18.5%
+290 bps
Core +330 bps
Acquisitions +105 bps
Other -145 bps
REVENUE
Amounts shown are in $ millions.

-- 7 of 16 --

Fourth Quarter 2020: Diagnostics
8
+23.5%
Core +21.5%
Acquisitions —%
FX +2.0%
Core +680 bps
Acquisitions — bps
Other — bps
+680 bps
OPERATING PROFIT MARGIN	REVENUE
Amounts shown are in $ millions.

-- 8 of 16 --

Fourth Quarter 2020: Environmental &
Applied Solutions
9
OPERATING PROFIT MARGIN
Core -180 bps
Acquisitions -30 bps
Other — bps
-210 bps
Amounts shown are in $ millions.
REVENUE
+2.0%
Core +1.0%
Acquisitions +0.5%
FX +0.5%

-- 9 of 16 --

10
GUIDANCE

-- 10 of 16 --

Q & A
11

-- 11 of 16 --



-- 12 of 16 --

13
Non-GAAP Reconciliations
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations 1
December 31, 2020 	December 31, 2019 	December 31, 2020 	December 31, 2019
1.66	$ 	1.07	$ 	4.89	$ 	3.26	$
Pretax amortization of acquisition-related intangible assets A
	0.45 	0.21 	1.55 	0.85
Pretax acquisition-related fair value adjustments to inventory and deferred revenue, incremental
transaction costs deemed significant and integration preparation costs, in each case related to the
acquisition of Cytiva B	
0.06 	0.04 	0.77 	0.13
Loss on early extinguishment of debt C
	0.04 	0.01 	0.04 	0.01
Loss on partial settlement of a defined benefit plan D
	- 	0.01 	- 	0.01
Pretax impairment charges related to a facility in the Diagnostics segment in the first quarter of 2020,
trade name and other intangible assets in the Environmental & Applied Solutions segment in the first
quarter of 2020 and trade names in the Environmental & Applied Solutions segment in the third
quarter of 2020 E	
- 	- 	0.03 	-
Pretax fair value (gains) and losses on the Company's equity and limited partnership investments F
(0.04) 	- 	(0.02) 	-
Gain on the sale of certain product lines in the Life Sciences segment in the second quarter of 2020 G
- 	- 	(0.62) 	-
Tax effect of all adjustments reflected above H
	(0.10) 	(0.05) 	(0.27) 	(0.17)
Discrete tax adjustments and other tax-related adjustments I
	- 	(0.02) 	(0.12) 	0.29
Declared dividends on the MCPS assuming “if-converted” method J
	0.01 	0.01 	0.06 	0.04
2.08	$ 	1.28	$ 	6.31	$ 	4.42	$
1
Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
December 31, 2020 	December 31, 2019 	December 31, 2020 	December 31, 2019
Average common stock and common equivalent shares outstanding - diluted 	724.5 	726.3 	718.7 	725.5
Converted shares 2 	19.6 	11.0 	17.1 	9.7
Adjusted average common stock and common equivalent shares outstanding - diluted 	744.1 	737.3 	735.8 	735.2
2
Each of the per share adjustment amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock.
Three-Month Period Ended
Diluted Net Earnings Per Common Share from Continuing Operations (GAAP)
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations (Non-GAAP)
Three-Month Period Ended
Year Ended
Year Ended
The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20 trading-day trailing volume weighted average price
(“VWAP”) of $223.43 and $150.10 as of December 31, 2020 and December 31, 2019, respectively.
A
December 31, 2020 December 31, 2019 	December 31, 2020 December 31, 2019
Pretax 	$ 	336 $ 	156 $ 	1,138 $ 	625
After-tax 	270 	125 	915 	504
B
C
D
E
F
G
H
I
J
Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the
amortization line item above):
Three-Month Period Ended
Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
Year Ended
Loss on early extinguishment of debt resulting from “make-whole” payments associated with the retirement of the 2022 Euronotes ($26 million pretax as reported
in this line item, $20 million after-tax) in both the three-month period and year ended December 31, 2020 and the 2020 U.S. Notes and the 2020 Assumed Pall
Notes ($7 million pretax as reported in this line item, $5 million after-tax) in both the three-month period and year ended December 31, 2019.
Loss on partial settlement of a defined benefit plan resulting from the transfer of a portion of Danaher's non-U.S. pension liabilities to a third party ($7 million
pretax as reported in this line item, $6 million after-tax) in both the three-month period and year ended December 31, 2019.
Pretax fair value (gains) and losses on the Company's equity and limited partnership investments recorded in the three-month period ($31 million pretax as
reported in this line item, $24 million after-tax) and year ended December 31, 2020 ($18 million pretax as reported in this line item, $14 million after-tax).
Pretax costs incurred for fair value adjustments to inventory and deferred revenue related to the acquisition of Cytiva in the three-month period ended December
31, 2020, ($49 million pretax as reported in this line item, $39 million after-tax) and fair value adjustments to inventory and deferred revenue, transaction costs
deemed significant and integration preparation costs related to the acquisition of Cytiva for the year ended December 31, 2020, ($568 million pretax as reported
in this line item, $450 million after-tax). Pretax costs incurred for transaction costs deemed significant and integration preparation costs related to the acquisition
of Cytiva in the three-month period ended December 31, 2019, ($30 million pretax as reported in this line item, $27 million after-tax) and the year ended
December 31, 2019, ($93 million pretax as reported in this line item, $84 million after-tax). The Company deems acquisition-related transaction costs incurred in
a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related
transaction costs typical for Danaher in a given period.
This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate
the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated
effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a
specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends
are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2020, include the impact of net discrete tax gains of $85 million (or
$0.12 per diluted common share), primarily related to the release of reserves for uncertain tax positions from audit settlements and expiration of statutes of
limitation and excess tax benefits from stock-based compensation, partially offset by a higher tax rate associated with the gain on the divestiture of certain product
lines in the Life Sciences segment and changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related
adjustments for the three-month period and year ended December 31, 2019, include the impact of net discrete tax gains of $12 million (or $0.02 per diluted
common share) and discrete tax charges of $215 million (or $0.29 per diluted common share), respectively. The discrete tax matters for the three-month period
and year ended December 31, 2019 relate primarily to changes in estimates associated with prior period uncertain tax positions and audit settlements, net of the
release of valuation allowances associated with certain foreign tax credits and tax benefits resulting from a change in law. The Company anticipates excess tax
benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the calculation of adjusted
diluted net earnings per common share from continuing operations.
In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS. In May 2020, the Company issued $1.72 billion in
aggregate liquidation preference of 5.0% MCPS. Dividends on the 4.75% and 5.0% MCPS are payable on a cumulative basis at an annual rate of 4.75% and
5.0%, respectively, on the liquidation preference of $1,000 per share. Unless earlier converted, each share of 4.75% MCPS will automatically convert on April
15, 2022 into between 6.6563 and 8.1538 shares of Danaher’s common stock, subject to further anti-dilution adjustments. Unless earlier converted, each share of
5.0% MCPS will automatically convert on April 15, 2023 into between 5.0081 and 6.1349 shares of Danaher’s common stock, subject to further anti-dilution
adjustments. The number of shares of Danaher’s common stock issuable on conversion of the MCPS will be determined based on the VWAP per share of the
Company's common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15,
2022 and April 15, 2023 for the 4.75% and 5.0% MCPS, respectively. For the purposes of calculating adjusted earnings per share, the Company has excluded the
paid and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding
applying the “if-converted” method of calculating share dilution are referred to as the “Converted Shares”.)
Pretax impairment charges related to a facility in the Diagnostics segment, trade name and other intangible assets in the Environmental & Applied Solutions
segment in the first quarter of 2020 ($8 million pretax as reported in this line item, $6 million after-tax) and trade names in the Environmental & Applied
Solutions segment in the third quarter of 2020 ($14 million pretax as reported in this line item, $11 million after-tax).
Pretax gain on the sale of certain product lines in the Life Sciences segment in the year ended December 31, 2020 ($455 million pretax as reported in this line
item, $305 million after-tax).

-- 13 of 16 --

14
Non-GAAP Reconciliations
Free Cash Flow from Continuing Operations
($ in millions)
December 31, 2020 	December 31, 2019
Cash Flows from (used in) Continuing Operations:
Operating Cash Flows from Continuing Operations (GAAP) 	6,215	$ 	3,657	$
Investing Cash Flows used in Continuing Operations (GAAP) 	(21,239)	$ 	(1,166)	$
Financing Cash Flows from Continuing Operations (GAAP) 	1,006	$ 	16,589	$
Free Cash Flow from Continuing Operations:
Operating Cash Flows from Continuing Operations (GAAP) 	6,215	$ 	3,657	$ 	~ 70.0%
Less: payments for additions to property, plant & equipment (capital expenditures) from continuing
operations (GAAP) 	(791) 	(636)
Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing
operations (GAAP) 	2 13
Free Cash Flow from Continuing Operations (Non-GAAP) 	5,426	$ 	3,034	$ 	~ 79.0%
We define free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant,
property and equipment from continuing operations (“capital disposals”).
Year Ended
Year-over-Year Change
Core Sales Growth and Core Sales Growth Including Cytiva
% Change Year Ended
December 31, 2020 vs.
Comparable 2019 Period
Total sales growth (GAAP) 	24.5%
Impact of:
Acquisitions/divestitures 	(18.0%)
Currency exchange rates 	-%
Core sales growth (non-GAAP) 	6.5%
Impact of Cytiva sales growth (net of divested product lines) 	3.0%
Core sales growth including Cytiva (non-GAAP) 	9.5%

-- 14 of 16 --

15
Non-GAAP Reconciliations

-- 15 of 16 --

16
Non-GAAP Reconciliations
Statement Regarding Non-GAAP Measures
•
•
•
•
o
o
o
Each of the non-GAAP measures set forth in this file should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP
measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful
information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the
corresponding GAAP measure, help our investors to:
with respect to adjusted diluted net earnings per common share, understand the long-term profitability trends of our business and compare our
profitability to prior and future periods and to our peers;
with respect to free cash flow, understand Danaher’s ability to generate cash without external financings, strengthen its balance sheet, invest in its
business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into
account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not
necessarily available for discretionary expenditures).
We also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life
Sciences business), which Danaher acquired from GE on March 31, 2020. Historically Danaher has calculated core sales solely on a basis that excludes sales
from acquired businesses recorded prior to the first anniversary of the acquisition. However, given Cytiva’s significant size and historical core sales growth
rate, in each case compared to Danaher’s existing businesses, management believes it is appropriate to also present core sales on a basis that includes
Cytiva sales. Management believes this presentation provides useful information to investors by demonstrating the impact Cytiva has on the Company’s
current growth profile, rather than waiting to demonstrate such impact 12 months after the acquisition when Cytiva would normally have been included in
Danaher’s core sales calculation. Danaher calculates period-to-period core sales growth including Cytiva by adding to the baseline period sales Cytiva’s
historical sales from such period (when it was owned by GE, as applicable), net of the sales of the divested product lines and also adding the Cytiva sales to
the current period.
with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our
The items we exclude from adjusted diluted net earnings per common share are excluded for the following reasons:
Amortization of Intangible Assets. We exclude the amortization of acquisition-related intangible assets because the amount and timing
of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a
history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s
purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from
acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time
between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe
however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible
asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
Restructuring Charges. We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of
the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity
improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the
core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in
a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.
Other Adjustments. With respect to the other items excluded (as applicable), we exclude these items because they are of a nature and/or
size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the
period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance
difficult.
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures
similar to adjusted diluted net earnings per common share and free cash flow in the Company’s executive compensation program.
•
•
•
•
• With respect to forecasted core sales and forecasted core sales including Cytiva, we do not reconcile these measures to the comparable GAAP measure
because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions and divested product
lines, which would be reflected in any forecasted GAAP revenue.
With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock
(“MCPS”) will mandatorily convert into Danaher common stock on the mandatory conversion date, which is expected to be April 15, 2022 and April 15,
2023 for the 4.75% and 5.0% MCPS, respectively (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of
designations). In this file, we use this measure to present the earnings per share-related non-GAAP measures on a basis that assumes the MCPS had
already been converted as of the beginning of the applicable period (and accordingly also exclude the dividends that were actually paid on the MCPS
during such period, since such dividends would no longer be paid once the MCPS convert). We believe this presentation provides useful information to
investors by helping them understand what the net impact will be on Danaher’s earnings per share-related non-GAAP measures once the MCPS convert
into Danaher common stock.
With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to the “other adjustments”, we
exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because
the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and
make comparisons of long-term performance difficult.
With respect to core sales and core sales including Cytiva, (1) we exclude the impact of currency translation because it is not under management’s
control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions (other than Cytiva, in the case of
core sales including Cytiva) and divested product lines because the timing, size, number and nature of such transactions can vary significantly from
period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term
performance difficult.
With respect to free cash flow, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to
demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.

-- 16 of 16 --